E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Announce First Quarter 2022 Financial Results on May 5
April 28, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Completes Sale of New Jersey Tax Benefits
April 26, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of its...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology
April 21, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frontiers in Neurology has published...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program
April 19, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore™ nVNS has been selected for...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance
April 12, 2022 08:00 ET | electroCore, Inc.
Record revenue from product sales will be approximately $1.9M; approximately 60% growth over first quarter 2021March 31, 2022, cash balance of approximately $29.9M ROCKAWAY, N.J., April 12, 2022 ...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Exclusive License Agreement with Teijin for Japan Territory
April 05, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Dr. Peter Staats to Keynote the Fifth Annual Bioelectronic Medicine Forum in New York
March 23, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced its co-founder and Chief...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Present at 2022 Maxim Virtual Growth Conference
March 22, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Fourth Quarter and Full Year 2021 Financial Results
March 10, 2022 16:01 ET | electroCore, Inc.
Full year 2021 net sales of approximately $5.5 million increased 56% over $3.5 million for full year 2020 Ended 2021 with cash and cash equivalents of $34.7 million Company to host conference call...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Changes to its Board of Directors
March 09, 2022 11:30 ET | electroCore, Inc.
ROCKAWAY, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Julie Bruzzone Goldstein...